Contineum Therapeutics officer proposes $56K sale

Earlier listed sales included 9,520 shares on September 1, 2026, and 9,520 shares on August 3, 2026.

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. (CTNM) officer Daniel Lorrain reported a proposed sale of 4,170 common shares, with an aggregate market value of $55,961.40, through Morgan Stanley Smith Barney LLC; the approximate sale date is October 1, 2026. The shares are listed as acquired from the issuer as restricted stock units on May 9, 2017. The notice also lists five earlier sales under its 10b5-1 Sales heading, dated July 8 through September 1, 2026.

Key Figures

Proposed common shares for sale: 4,170 shares Aggregate market value: $55,961.40 Shares outstanding: 32,958,632 shares +5 more

8 metrics

Proposed common shares for sale 4,170 shares Approximate sale date: October 1, 2026

Aggregate market value $55,961.40 Proposed sale

Shares outstanding 32,958,632 shares Count listed in the securities information

Earlier sale 9,520 shares September 1, 2026; listed under 10b5-1 Sales

Earlier sale 9,520 shares August 3, 2026; listed under 10b5-1 Sales

Earlier sale 127 shares July 31, 2026; listed under 10b5-1 Sales

Earlier sale 25 shares July 9, 2026; listed under 10b5-1 Sales

Earlier sale 1,015 shares July 8, 2026; listed under 10b5-1 Sales

Key Terms

Restricted Stock Units, 10b5-1 Sales, Aggregate market value

3 terms

Restricted Stock Units financial

"Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

10b5-1 Sales regulatory

"10b5-1 Sales for DANIEL LORRAIN"

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

Aggregate market value financial

"4170 | 55961.40"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CTNM shares does Daniel Lorrain propose to sell?

Daniel Lorrain's notice lists a proposed sale of 4,170 common shares, with an aggregate market value of $55,961.40 and an approximate sale date of October 1, 2026. Morgan Stanley Smith Barney LLC is listed in connection with the sale.

What earlier sales does Daniel Lorrain's CTNM notice list?

It lists sales of 9,520 shares on September 1, 2026; 9,520 on August 3, 2026; 127 on July 31, 2026; 25 on July 9, 2026; and 1,015 on July 8, 2026, under the 10b5-1 Sales heading.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 04:21 PM Accepted by SEC EDGAR 10/01/2026 - 04:21 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001861550
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Contineum Therapeutics, Inc.
SEC File Number	001-42001
Address of Issuer	3565 General Atomics Court, Suite 200 San Diego CALIFORNIA 92121
Phone	8583335280
Name of Person for Whose Account the Securities are To Be Sold	Daniel Lorrain
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4170	55961.40	32958632	10/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/09/2017	Restricted Stock Units	Issuer			4170	05/09/2017	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for DANIEL LORRAIN 3565 General Atomics Court, Suite 200 San Diego CA 92121	Common	09/01/2026	9520	154895.52
10b5-1 Sales for DANIEL LORRAIN 3565 General Atomics Court, Suite 200 San Diego CA 92121	Common	08/03/2026	9520	151792.08
10b5-1 Sales for DANIEL LORRAIN 3565 General Atomics Court, Suite 200 San Diego CA 92121	Common	07/31/2026	127	2032.00
10b5-1 Sales for DANIEL LORRAIN 3565 General Atomics Court, Suite 200 San Diego CA 92121	Common	07/09/2026	25	400.00
10b5-1 Sales for DANIEL LORRAIN 3565 General Atomics Court, Suite 200 San Diego CA 92121	Common	07/08/2026	1015	16240.00

144: Remarks and Signature

Remarks
Date of Notice	10/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/23/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Lorrain
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)